---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-276019"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:30:45.891490+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PepGen reports Q3 net loss of $18.0M; 53.7% splicing correction in DM1 Phase 1

## Summary
- FREEDOM-DM1 15 mg/kg showed mean splicing correction of 53.7%, highest reported in DM1 patients.
- All patients in FREEDOM2 5 mg/kg cohort enrolled; topline data expected Q1 2026.
- Closed $115M public offering in Sept 2025; cash runway extended into H2 2027.
- Net loss $18.0M ($0.52/sh) vs $21.4M ($0.66/sh) in Q3 2024; cash $163.7M at Sept 30.
- R&D expense $13.4M down from $17.7M YoY; G&A flat at $5.2M.

## SEC filing metadata
- accession: 0001193125-25-276019
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000119312525276019/0001193125-25-276019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000119312525276019/pepg-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-276019
- JSON: https://secwatch.observer/filing/0001193125-25-276019.json
- Plain text: https://secwatch.observer/filing/0001193125-25-276019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.